231 S. Whisman Rd
5 articles with SanBio
AANS 2019: SB623 Demonstrated Statistically Significant Improvement in Motor Function Among Patients with Chronic Motor Deficit from Traumatic Brain Injury (TBI)
Positive results from the STEMTRA Phase 2 trial were presented today at the American Association of Neurological Surgeons (AANS) annual scientific meeting
SanBio Announces SB623 Regenerative Cell Therapy for Traumatic Brain Injury Has Received Ministry of Health, Labour and Welfare (MHLW) Sakigake Designation
The SanBio Group announced that SB623, a regenerative cell therapy that the Group is developing globally for the treatment of chronic motor deficit resulting from traumatic brain injury (TBI), has received the Sakigake Designation for innovative medical products from the Ministry of Health, Labour, and Welfare (MHLW) of Japan.
The SanBio Group has updated part of its March 13, 2018 release “Update on Development Progress of Regenerative Cell Medicine SB623”.
SanBio Reaches Agreement on Manufacture of Regenerative Medicine Product SB623 with Hitachi Chemical
SanBio Group and Hitachi Chemical Co., Ltd. jointly announced that, through an agreement with Hitachi Chemical Advanced Therapeutics Solutions, LLC, they will manufacture SB623, a proprietary regenerative medicine product under development by SanBio.
SanBio and Teijin Limited jointly announced today that they would terminate the exclusive licensing agreement signed in 2009 regarding the development and marketing of SB623 for stroke treatment in Japan.